Core Viewpoint - Lide Health Technology (Guangzhou) Co., Ltd. has successfully completed a multi-million yuan Pre-A round financing, aiming to enhance its capabilities in AI life science instruments and biomanufacturing equipment, aligning with national strategic goals in the "14th Five-Year Plan" [4][8]. Group 1: Company Overview - Since its operation began in March 2024, Lide Health has established a multidisciplinary team of over 100 members, with more than 60% being R&D personnel, covering various fields such as AI, optics, mechanics, and biology [5]. - The company has launched over 10 high-end AI life science instruments and services, including AI models for cell identification and high-throughput imaging systems, addressing inefficiencies and high costs in traditional life sciences [5][6]. Group 2: Future Product Development - Lide Health plans to continue developing competitive product solutions, including virtual cell AI models and high-throughput drug screening systems, to provide large-scale, high-quality data production tools for the AI for Science sector [6]. - The company has built several innovative laboratories to prepare for large-scale production and delivery of its products [6]. Group 3: Intellectual Property and Standards - Lide Health has applied for over 110 patents, with around 50% being invention and PCT international patents, and has been recognized as an excellent case for patent transformation by the National Intellectual Property Administration [7]. - The company has participated in the formulation of 26 standards, including 7 national standards, promoting the automation and intelligent transformation of the life sciences sector [7]. Group 4: Investment and Market Position - The lead investor in the Pre-A round highlighted Lide Health's exceptional technological innovation and industrialization capabilities, aligning with national strategic directions and industry trends [8]. - The company has signed contracts worth several million yuan with nearly 100 leading clients, including top universities, research institutions, and major biopharmaceutical companies [6].